FRONZA, MARZIA
 Distribuzione geografica
Continente #
EU - Europa 11.239
NA - Nord America 365
AS - Asia 72
Totale 11.676
Nazione #
IT - Italia 11.175
US - Stati Uniti d'America 363
CN - Cina 43
SE - Svezia 40
SG - Singapore 20
FI - Finlandia 9
UA - Ucraina 5
IN - India 3
CA - Canada 2
DE - Germania 2
ES - Italia 2
GB - Regno Unito 2
SA - Arabia Saudita 2
VN - Vietnam 2
AT - Austria 1
CZ - Repubblica Ceca 1
FR - Francia 1
IR - Iran 1
KR - Corea 1
NL - Olanda 1
Totale 11.676
Città #
Cagliari 10.700
Uta 433
Chandler 55
Boardman 41
Nyköping 38
Fairfield 37
Ashburn 36
Seattle 17
Woodbridge 17
Shanghai 16
Cambridge 15
New York 15
Houston 13
Wilmington 10
Boston 9
Helsinki 9
Rome 9
Ann Arbor 8
Singapore 8
Dearborn 7
San Diego 6
Chicago 3
Jacksonville 3
Nanchang 3
Phoenix 3
Shenyang 3
Taizhou 3
Assemini 2
Atlanta 2
Beijing 2
Catania 2
Dong Ket 2
Granada 2
Hangzhou 2
Hebei 2
Jeddah 2
Menlo Park 2
Norwalk 2
Orange 2
Pignone 2
Redwood City 2
Toronto 2
Amsterdam 1
Ardabil 1
Baotou 1
Bologna 1
Brixen 1
Brno 1
Capoterra 1
Carmine 1
Hefei 1
Jiaxing 1
Jinan 1
Jinhua 1
Kilburn 1
Kunming 1
Leawood 1
Levico Terme 1
London 1
Mumbai 1
Palermo 1
Pune 1
Quartu Sant'elena 1
Seoul 1
Stockholm 1
Taio 1
Treviso 1
Verona 1
Vienna 1
Washington 1
Zhengzhou 1
Totale 11.576
Nome #
Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers 3.513
Cognition in multiple sclerosis: Between cognitive reserve and brain volume 2.701
Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study 1.949
Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study 837
Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium 485
What happens after fingolimod discontinuation? A multicentre real-life experience 407
An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis 406
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients 345
Brain Volume and Perception of Cognitive Impairment in People With Multiple Sclerosis and Their Caregivers 335
The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility 282
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study 279
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 108
Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination 76
Totale 11.723
Categoria #
all - tutte 15.543
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.543


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.640 0 0 0 27 595 480 249 64 40 39 43 103
2020/20212.801 81 152 140 742 431 332 165 165 111 182 183 117
2021/2022891 59 29 47 62 38 26 34 53 114 117 168 144
2022/20231.628 100 243 247 129 123 223 92 109 88 85 108 81
2023/20241.677 167 86 60 96 143 272 221 146 80 125 145 136
2024/20252.188 697 891 352 248 0 0 0 0 0 0 0 0
Totale 11.723